Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | XIAP | P98170 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 9/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4841061 | 0.92 | ATM (0.45) | LMNAATMTRPA1TP53L3MBTL1 | |
| SCHEMBL4033992 | 0.91 | RAB9A (0.44) | LMNAXIAPATMTRPA1TP53 | |
| SCHEMBL4033474 | 0.91 | PKM (0.44) | LMNAATMTRPA1TP53L3MBTL1 | |
| SCHEMBL4038964 | 0.88 | ALDH1A1 (0.42) | LMNAXIAPATMTRPA1TP53 | |
| SCHEMBL3825818 | 0.86 | XIAP (0.40) | LMNAXIAPATMTRPA1TP53 | |
| SCHEMBL4840572 | 0.85 | LMNA (0.41) | LMNAXIAPTRPA1TP53RORC | |
| SCHEMBL4842724 | 0.84 | TRPA1 (0.40) | LMNAXIAPTRPA1TP53RORC | |
| SCHEMBL4837872 | 0.82 | MMP8 (0.45) | LMNAL3MBTL1PTGER3TDP1 | |
| SCHEMBL4039505 | 0.82 | TRPA1 (0.43) | TRPA1PKM | |
| SCHEMBL4032871 | 0.81 | LMNA (0.39) | LMNAXIAPATMTRPA1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885695-B8 | INDOLINE COMPOUNDS | FOURNIER LAB SA (FR) | 2009-08-12 | — | — | EP | disclosed |
| EP-1885695-B1 | INDOLINE COMPOUNDS | FOURNIER LAB SA (FR) | 2009-02-25 | — | — | EP | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| EP-1885695-A2 | NOVEL INDOLINE COMPOUNDS | LABORATOIRES FOURNIER S.A. (FR) | 2008-02-13 | — | — | EP | disclosed |
| WO-2007000550-A2 | NOVEL INDOLINE COMPOUNDS | LABORATOIRES FOURNIER S.A. (FR) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | LMNA 1943/4885XIAP 4064/4885ATM 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.